Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Announces 33% Staff Cut, Will Focus Internally On Two Lead RNAi Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.

Advertisement

Related Content

Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results
Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn
Genzyme’s Asian Expertise Drives Alnylan Co-Development Pact For TTR Candidates
Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates
Deals Of The Week: Sunovion/Elevation, Janssen/Genmab, Alnylam/Monsanto
Ag-Bio Alliance With Monsanto Brings Alnylam Cash For “5x15” Programs
Alnylam CEO John Maraganore: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Alnylam CEO John Maraganore – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel